Can 'humanized' mice improve drug development in the 21st century?

Trends in Pharmacological Sciences

Volumn 34, Issue 5, 2013, Pages 255-260

  Peltz, Gary ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

chimeric mice; drug metabolism; liver humanization; predicting drug toxicity

Indexed keywords

DRUG METABOLITE; FIALURIDINE; THYMIDINE KINASE; UROKINASE;

CHIMERA; DNA MODIFICATION; DRUG CLEARANCE; DRUG METABOLISM; DRUG RESEARCH; DRUG RESPONSE; DRUG SAFETY; DRUG TRANSFORMATION; EXPERIMENTAL MOUSE; GENE EXPRESSION; GENE INACTIVATION; GENETIC ENGINEERING; IMMUNE DEFICIENCY; LIVER TOXICITY; MOUSE; MOUSE MUTANT; NONHUMAN; PHARMACOGENETICS; PRIORITY JOURNAL; REVIEW; THYMIDINE KINASE GENE; TRANSGENE;

ANIMALS; CHIMERA; DRUG DISCOVERY; HUMANS; LIVER; MICE; MICE, KNOCKOUT; MODELS, ANIMAL; TOXICITY TESTS;

EID: 84876891474     PISSN: 01656147     EISSN: 18733735     Source Type: Journal    
DOI: 10.1016/j.tips.2013.03.005     Document Type: Review

References (37)

1. S. Anderson Predicting circulating human metabolites: how good are we? Chem. Res. Toxicol. 22 2009 243 256
2. D. Walker A holistic strategy for characterizing the safety of metabolites through drug discovery and development Chem. Res. Toxicol. 22 2009 1653 1662
3. L. Leclercq Which human metabolites have we MIST? Retrospective analysis, practical aspects, and perspectives for metabolite identification and quantification in pharmaceutical development Chem. Res. Toxicol. 22 2009 280 293
4. D.A. Smith, and R.S. Obach Metabolites in safety testing (MIST): considerations of mechanisms of toxicity with dose, abundance, and duration of treatment Chem. Res. Toxicol. 22 2009 267 279
5. F.P. Guengerich, and J.S. MacDonald Applying mechanisms of chemical toxicity to predict drug safety Chem. Res. Toxicol. 20 2007 344 369
6. L.J. Lesko, and S. Schmidt Individualization of drug therapy: history, present state, and opportunities for the future Clin. Pharmacol. Ther. 92 2012 458 466
7. Y. Guo Pharmacogenomics and drug development Pharmacogenomics 6 2005 857 864
8. E.P. Sandgren Complete hepatic regeneration after somatic deletion of an albumin-plasminogen activator transgene Cell 66 1991 245 256
9. P. Meuleman Morphological and biochemical characterization of a human liver in a uPA-SCID mouse chimera Hepatology 41 2005 847 856
10. +/+-SCID mouse with humanized liver as a model for in vivo metabolism of 4-androstene-3,17-dione Drug Metab. Dispos. 37 2009 2367 2374
11. C. Tateno Near completely humanized liver in mice shows human-type metabolic responses to drugs Am. J. Pathol. 165 2004 901 912
12. M. Katoh, and T. Yokoi Application of chimeric mice with humanized liver for predictive ADME Drug Metab. Rev. 39 2007 145 157
13. H. Suemizu Establishment of a humanized model of liver using NOD/Shi-scid IL2Rgnull mice Biochem. Biophys. Res. Commun. 377 2008 248 252
14. -/- mice Nat. Biotechnol. 25 2007 903 910
15. S.D. Cederbaum Amino acid metabolism D.L. Rimoin, Principles and Practice of Medical Genetics 3rd edn 1997 Churchill Livingstone 1872 1875
16. M. Ito NOD/SCID/γc null mouse: an excellent recipient mouse model for engraftment of human cells Blood 100 2002 3175 3182
17. M. Hasegawa The reconstituted 'humanized liver' in TK-NOG mice is mature and functional Biochem. Biophys. Res. Commun. 405 2011 405 410
18. T. Nishimura Using chimeric mice with humanized livers to predict human drug metabolism and a drug-drug interaction J. Pharmacol. Exp. Ther. 344 2013 388 398
19. Y. Hu Human pharmacogenetic analysis in chimeric mice with 'humanized livers' Pharmacogenet. Genomics 344 2013 388 396
20. A.A. Chen Humanized mice with ectopic artificial liver tissues Proc. Natl. Acad. Sci. U.S.A. 108 2011 11842 11847
21. M. Katoh In vivo drug metabolism model for human cytochrome P450 enzyme using chimeric mice with humanized liver J. Pharm. Sci. 96 2007 428 437
22. O.J. Pozo Detection and structural investigation of metabolites of stanozolol in human urine by liquid chromatography tandem mass spectrometry Steroids 74 2009 837 852
23. H. Kamimura Assessment of chimeric mice with humanized liver as a tool for predicting circulating human metabolites Drug Metab. Pharmacokinet. 25 2010 223 235
24. S. Sanoh Prediction of in vivo hepatic clearance and half-life of drug candidates in human using chimeric mice with humanized liver Drug Metab. Dispos. 40 2012 322 328
25. S. Sanoh Predictability of metabolism of ibuprofen and naproxen using chimeric mice with human hepatocytes Drug Metab. Dispos. 40 2012 2267 2272
26. +/+)/SCID mouse model with a humanized liver for prediction of human metabolism Xenobiotica 41 2011 464 475
27. K-D. Bissig Human liver chimeric mice provide a model for hepatitis B and C virus infection and treatment J. Clin. Invest. 120 2010 650 653
28. E. Ohara Elimination of hepatitis C virus by short term NS3-4A and NS5B inhibitor combination therapy in human hepatocyte chimeric mice J. Hepatol. 54 2011 872 878
29. M.R. Trusheim Quantifying factors for the success of stratified medicine Nat. Rev. Drug Discov. 10 2011 817 833
30. R. Weinshilboum, and L. Wang Pharmacogenomics: bench to bedside Nat. Rev. Drug Discov. 3 2004 739 748
31. L. Zhang Drug interactions evaluation: an integrated part of risk assessment of therapeutics Toxicol. Appl. Pharmacol. 243 2010 134 145
32. C. Bode The nasty surprise of a complex drug-drug interaction Drug Discov. Today 15 2010 391 395
33. H. Okumura Humanization of excretory pathway in chimeric mice with humanized liver Toxicol. Sci. 97 2007 533 538
34. Y. Sato Human hepatocytes can repopulate mouse liver: histopathology of the liver in human hepatocyte-transplanted chimeric mice and toxicologic responses to acetaminophen Toxicol. Pathol. 36 2008 581 591
35. R. McKenzie Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B N. Engl. J. Med. 333 1995 1099 1105
36. E.W. Lee Identification of the mitochondrial targeting signal of the human equilibrative nucleoside transporter 1 (hENT1): implications for interspecies differences in mitochondrial toxicity of fialuridine J. Biol. Chem. 281 2006 16700 16706
37. K. Fattinger The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions Clin. Pharmacol. Ther. 69 2001 223 231